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ABSTRACT 
Theranostics is an emerging field of medicine that uniquely 
combines drugs and/or techniques to simultaneously 
or sequentially diagnose and treat medical conditions. 
Proteomics, the large-scale characterisation of proteins, 
is now being applied in theranostics. The proteome is the 
entire set of proteins that is produced by an organism. It 
varies tempora lly and spatially according to the distinct 
needs of the organism. Major breakthroughs in human 
proteomics are seen in its theranostics applications as 
biomarkers (e.g. in cancer, Alzheimer's disease, various 
other neurodegenerative disorders, autism, cardiovascular 
diseases) and in therapeutics (e.g. personalised treatment). 
INTRODUCTION 
Proteomics is the analytical study of all proteins transcribed 
by a genome.1 It was Anderson and Anderson in 1977 who 
pioneered in this field by studying human plasma proteins. 
They even predicted that someday all proteins in the 
human body could be identified.2 
Human proteomics is catalysing a new research field 
that has the potential to be translated into the clinical 
setting. This 'clinical proteomics' is trying to understand 
what, how much and when, certain proteins are expressed 
in health and disease. Thus, it has the potential to help in 
the discovery of novel biomarkers of disease processes 
and help to improve their d iagnosis and prognosis.3·5 
Also proteomic profi les have g reat potential to unvei l 
pathophysiological circuits associated with pathology 
of disease and these may provide targets for new 
treatments or prevention. They can also offer novel ways for 
personalised therapeutics. 
Amongst the main crucial technologies that are used 
to identify, quantify and characterise the proteins (and 
hence describe the proteomic signatures or profiles) of 
normal and disease processes, a combination of mass 
spectrometry,6 two-dimensional electrophoresis7 and 
bioinformatics is applied. These powerful technologies, 
especially quantitative MS and bioinformatics, have 
made great advances and today it is possible to analyse 
complex mixtures of proteins in a more rapid, accurate and 
quantitative way. The field of bioinformatics has advanced 
to meet the need for data acquisition, interpretation and 
presentation. These great advances are helping to discover 
the function of proteins and the underlying pathological 
mechanisms of disease. 
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1. PROTEOMICS IN CARDIOVASCULAR DISEASES 
Arrell et al.8 found that in patients with di lated 
cardiomyopathy (DCM) there are 88 myocardial proteins 
which have decreased expression. They proposed that this 
low myocardial protein profi le can be used as a diagnostic 
and prognostic signature for DCM. 
Borozdenkova et al.9 studied proteomic signatures as 
potential markers for rejection afte r heart transplants. Of 
the 100 proteins that they found to be overexpressed, 13 
were specific to heart tissue. Of these 13, two proteins, 
tropomyosin and alpha beta-crystallin, were measurable in 
the serum of patients having rejection after 3 months. 
As mentioned, proteomic bio-profiles can reveal 
pathophysiological circuits associated with pathology 
(causation and progression) and these can provide 
targets for new treatments or prevention. In keeping 
with this Ferreira et al .10 initially identified 252 proteins 
in the plasma of heart failure patients. After factoring a 
number of variables, the number of circulating plasma 
proteins associated with heart failure pathophysiology 
was decreased to 38. These were specifically linked 
by the authors to apoptosis, inflammation, vascular 
physiology, remodelling of matrix, control of blood 
pressure, and d1olesterol metabolism [ClinicalTrials.gov 
Identifier: NCT025S6450J. 
Further to this, Lind et al.11 have worked on a proteomic 
chip to discover new biomarkers for AF. Using this chip 
they discovered that four other proteins, specifically 
FABP4, IL-6, TIM-1 and AM, besides the already known 
ones (i.e. NT-pro-BNP, FGF-23, GDF- 15) are linked to the 
development of AF. 
2. PROTEOMICS IN MENTAL ILLNESS 
The underlying pathophysiology of mental illness 
remains unclear. Proteomics is one tool that has the 
potential to objectively help this situation and thus a id in 
their theranostics. 
Xu HB et al.12 analysed the plasma proteomes of 
patients with major depressive disorders and healthy 
controls. They showed expression of altered proteins 
(A2M and isoform-1 of VDP) involved in immunoregulation 
and lipid metabolism. They proposed that disruption 
in immunoregulation and lipid metabolism might be 
implicated in the pathological mechanisms of major 
depressive disorders. 
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In a similar but more recent proteomic study, Smimova 
et al. 13 also showed differences in the serum proteomes 
of schizophrenia and bipolar disorder.14 Speoifically, they 
discovered 27 proteins for schizophrenia, and 18 proteins 
for BD. In schizophrenia, the proteins were linked to the 
immune response, cell growth and maintenance, cell 
communication, and to the regulation of metabolism 
of proteins and of nucleic acids. In BD, the proteins 
were linked to the immune response, cell membrane 
transportation, communication of cells and their growth, 
and to neurons and oligodendrocyte development 
As with other proteomic studies in other areas such 
results will eventually surely unveil the intricate pathways 
of psychotic disorders with beneficial outcomes in 
management within the clinical setting. 
3 . PROTEOMICS IN AUTO-IMMUNE DISEASES 
Proteomics is also being app lied in auto·immune disease. 
Wu et al.'~ d iscovered potential biomarkers for systemic 
lupus erythematosus (SLE). In this study, SLE serum 
autoantibodies were val idated using serum samples 
from 306 participants. Four peptides (SLE2018Val001, 
SLE2018Val002, SLE2018Val006, and SLE2018Val008) were 
identified as being able to d ifferentiate SLE patients from 
healthy controls. Wu et al. propose that their approach 
could be implemented to identify autoantibodies in 
other diseases. 
Xu et al. 16 investigated 106 proteins in patients with 
psoriasis which are involved in several biological signalling 
pathways relevant in the disease. Following a comparison 
with a healthy cohort, the authors found that, of these 
106 proteins,58 are only found in psoriatic patients. From 
these 58, 21 proteins have been identified as markers for 
treatment outcomes. Furthermore, 3 proteins showed a 
reliable correlation with the severity of the disease. 
In rheumatoid arthritis, serum amyloid A (SAA) and 
S100 have already been identified as potential biomarkers. 
Nys et al.17 furthered the research and found thatthere is a 
negative relationship between the subtypes of SAA, SAA 1 a 
and SAA 1 p for early·onset RA. They also found that isoform 
SAA2 and S1 00A8/S100A9 proteins are overexpressed 
irrespective of the RA phase. They propose that these 
findings might be indicators of other unknown pathways 
of the d isease. 
Another proteomic study in RA patients was done 
by Chen et al.18 They analyzed biomarkers to distinguish 
responders to triple therapy (methotrexate, leflunomide 
and infliximab). They analysed 51 proteins that were 
expressed differently in responders and non-responders. 
Such proteins in proteomics are called differentially 
expressed proteins (DEPs). Of these DEPs 5 were 
significantly up·regulated whilst another 5 were down-
regulated. This study shows how proteomics can be used 
as a tool to predict clinical response. 
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4. PROTEOMICS IN MULTIPLE SCLEROSIS 
Malekzadeh et al.19 studied DEPs during the progression 
of MS. The study was spread over 4 years and involved a 
cohort of healthy individuals and 3 cohorts of MS patients 
with 3 different rates of progression. Importantly they found 
8 potential biomarkers, including LGLAS8, CCL3, RGMA, 
C3, FGF9, and EHMT2. These proteins are associated with 
complement pathways, activation of the immune system, 
and cell-cell and cell-matrix adhesions. The authors of 
the study propose that these proteins are involved in the 
progression of MS and they envisage further research to 
use them in the clinical setting. 
5. PROTEOMICS IN INFLAMMATORY BOWEL DISEASE 
(IBD) 
Ning Let a1.20 compared proteomic profiles of intestinal 
tissue taken from healthy individuals, and patients with IBD, 
specifica lly Crohn's disease (CD) and ulcerative colitis. They 
found several DEPs, like angiotensin converting enzyme 2 
(ACE2) and angiotensin converting enzyme 1 (ACE), being 
overexpressed. Such overexpression was more marked in 
CD. Most importantly they found overexpression of CD38 
in inflamed tissue. This is a protein which is intricate in the 
nicotinamide adenine dinucleotide (NAD}10 metabolism. 
They proposed that this finding might need to be followed 
further to study the function of CD38 and NAD metabolism 
in intestinal inflammation. 
On the other hand Lehmannet al.21 compared fecal 
samples taken from patients with CD and UC via a 
metaproteomic approach. Importantly they found that CD 
and UC patients showed underex:pression of human lgA 
and the protein RprY from Bacillus fragilis. However, in 
CD they found an overexpression of the enzyme sucrose-
isomaltase. The authors concluded that that, following 
validation, their feca l metaproteomic approach could be 
used as a non-invasive way in the diagnosis of CD and UC. 
6. PROTEOMICS IN AUTISM 
Various causes have been implied in the pathophysiology 
of autism, but the exact mechanisms remain e lusive. 
Proteomic studies might prove to be useful to uncover 
these. Junaid et al.22 used a proteomic profiling method 
on autopsied brains of Autism Spectrum Disorder 
patients. They discovered an abnormal protein pattern 
as a result of an aberrant gene expression in their grey 
matter. Specifically, they found reduced glyoxalase 1 
expression and propose that this gene might be a possible 
aetiological factor. 
In another proteomic analytical study to unveil 
the underlying mechanisms in aut ism, Corbett et al.23 
compared protein profiles from two groups of children, 
one group comprising autistic children and the other 
comprising a cohort of normal children as control. 
The study showed that in the autistic group, there was 
an increased expression of Apolipoprotein B-100, 
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Complement Factor H Related Protein (FHR1 ). Complement 
C1q and Fibronectin 1 (FN1 ). The authors proposed that 
these differences might be aetiological factors in the 
abnormal brain development in autistic children. 
7 . PROTEOMICS IN CANCER 
Proteomic studies are also being integrated with other 
studies like genomics and transcriptomics. This augments 
the discovery of the molecular players involved in the 
pathophysiology of diseases, including cancer. A case in 
point is the study carried out by Wu et al.24 Here, analysis 
of proteomic and transcriptomic profiles showed that the 
long non-coding RNA molecule HOTAIR (HOX Transcript 
Antisense lntergenic RNA), which has been implicated 
in human tumorigenesis, also shows dysregulation in 
hepatocel lular carcinoma (HCC). Specifically, HOT AIR 
inhibit ion was found to be associated with dysregulation of 
several transcripts and proteins. Functional b ioinformatic 
studies of the data collected showed that these transcripts 
and proteins relate to biological circuits in cancer. 
Furthermore, the study showed that HOTAIR caused cell 
proliferation partly by its regulation of OGFr expression 
(opioid growth factor receptor), the latter being known to 
have a negative regulation on cell proliferation in HCC. 
HOTAIR is also dysregulated (specifically it is 
overexpressed) in breast cancer. This over-expression is 
responsible in metastasis through HOTAIR recruitment of 
another complex molecule called Polycomb repressive 
complex 2 (PRC2), which then silences additional genes, 
besides the HOXD gene cluster. In 2016 Meredith et al.25 
carried out a proteomic analysis and found that other 
proteins are associated with HOTAIR's action. One such 
significant interaction is that between HOTAIR and hnRNP 
(heterogeneous nuclear ribonucleoprotein) A2/B1. This 
interaction is central to chromatin structure regulation 
in cells of breast cancer. Indeed, the authors found 
that knocking down A2/B 1 reduced PRC2 activity and 
also cell invasion. 
8. PROTEOMICS IN OBSTETRICS 
AND GYNAE DISORDERS 
Tarca et al.26 carried out a study comparing plasma 
proteins bio-profiles in 90 normal pregnant women and 
33 who had early pre-eclampsia. They discovered that a 
specific proteomic signature preceded pre·eclampsia. 
Specifically, at 16-22 weeks matrix metalloproteinase-7 
and glycoprotein llb/llla complex were overexpressed 
and could be used as reliable predictors. Predictors from 
22-28 weeks were increased levels of sialic acid binding 
immunoglobulin-like lectin 6 (siglec-6) and activin-A, and 
decreased levels of isoform 121 (VEGF-121 ), placental 
growth factor (PIGF) and vascular endothelial growth 
factor A. From 28 weeks to 32 weeks, the best biomarkers 
were activated leukocyte cell adhesion molecule, 
siglec-6, and VEGF-121. 
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In 2019 Eckert et al.27 used proteomics to characterise 
pivotal molecules in ovarian cancer, studying the latter 
phenotype in-situ and its progression in metastasis. 
They discovered that methyltransferase nicotinamide 
N-methyltransferase (NNMT) and the proteins that it 
regulates underpins metastasis. Specifically, they revealed 
that over-expression of NNMT leads to ovarian cancer 
cells to migrate and proliferate, causing also a reduction 
of histone methylation and S-adenosyl methionine. 
These epigenetic changes caused a global change in 
gene expression associated with the ovarian cancer 
phenotype behaviour. 
9. PROTEOMICS IN NEURODEGENERATIVE DISORDERS 
Mining large data from proteomics, Deolankar et al .28 
propose a new [pathway to diagnosis and treat Alzheimer's 
disease. Specifically, they used spectral data to sieve for 
protein post-translational modifications, and indeed, 
found proteins modified post-translationally. They propose 
that these may be used as b iomarkers for d iagnosis o r as 
molecular targets for treatment in AD. Of the many novel 
proteins found, 13 of them showed high expression. 
Mallah et al.29 employed a micro-proteomic platform 
to find spatiotemporal signatures of protein markers after 
traumatic brain injuries (TBI) in a rat model. Specifically, 
they analysed different brain regions at 1 day, 3 days, 7 
days, and 10 days, post-injury. They found that there was an 
over-expression of proteins that are similarly expressed in 
Parkinson's disease. Amongst these were GPR158, HGMB 1, 
Synaptotagmin and Glutamate Decarboxylase in ipsilateral 
substantia nigra. The authors propose that their study 
shows a possible link for PD or Parkinsonism post-TBI. 
Amyotrophic lateral sclerosis14 and frontotemporal 
dementia (FTD) are two neurodegenerative disorders 
whose pathophysiology is yet not clear even though the 
culprits may be the aggregation of abnormal proteins in 
neurons which lead to their degeneration. The proteins 
that have been i mplicated are tau, superoxide dismutase 
1 (SOD1) and TAR DNA binding protein of 43 kDa (TDP-
43). In this regard, Hedl et al.30 discuss new technologies 
and approaches like SILAC (stable isotope labelling by 
amino acids in cell cu lture), IP·MS (immunoprecipitation 
mass spectrometry) and BiolD (biotin identification), 
the latter two being PPI (protein·protein interaction) 
techniques. These proteomic approaches are high-
throughput, quantitative and unbiased. Moreover, they are 
novel avenues that can be used to unveil the mechanisms 
of pathology, biomarkers and therapeutic targets 
for ALS and FTD. 
1 O. PROTEOMICS IN OBESITY 
It is a well-known fact that, following bariatric surgery, 
those obese diabetic patients showing insulin resist ance, 
have their glucose levels controlled, notably after the 
biliopancreatic diversion, BPD. ClinicalTrials.gov Identifier. 
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NCT01151917 (2009) conducted between 2009 and 
2012employed a proteomic platform to investigate the 
proteins and peptides that underlie the mechanisms 
involved in the glycaemic restoration after BPD. 
Indeed, Nicolai et al.3' used mass spectrometry 
and identified a low-abundance peptide that regulates 
glucose and appetite. Specifically, they discovered that the 
secretion of oxyntomodulin, a gut hormone, is increased 
10-fold after the gastric bypass in type 2 diabetic patients. 
They also found that oxyntomodulin is co-secreted with 
g lucagon-like peptide-1 (GLP-1 ), another gut hormone. 
Moreover, oxyntomodulin acts using the same receptor as 
GLP-1 and is deactivated by the same protease that breaks 
down the latter. Thus, they proposed that oxyrntomodulin 
and GLP-1 may regulate glucose metabolism and appetite. 
Such discoveries of low-abundance regulatory peptides 
show again that the proteomic approach has g reat 
potential in therapeutic translational research, namely that 
of providing new ways to treat insulin resistance. 
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Indeed, hot spots on suspected culprit proteins are 
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therapeutic drugs. 
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